ClinicalTrials.Veeva

Menu

Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound (PO-PID)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Lung Diseases, Interstitial
Lung Diseases
Rheumatoid Arthritis

Treatments

Other: Lung sonography

Study type

Observational

Funder types

Other

Identifiers

NCT04195789
69HCL19_0859

Details and patient eligibility

About

The high resolution chest scan is the gold standard for the screening of interstitial lung disease, but this remains an onerous examination, and irradiating.

Ultrasound could be used to detect these disorders with a very good sensitivity and specificity. This exam offers the advantage of being non radiating, inexpensive, and accessible to the rheumatologist who already uses it in their daily practice.

The investigators want to assess the lung ultrasound performance compared with the gold standard.

Patients will be included during a regular follow-up consultation with their referent rheumatologist. If there is an indication of first line biotherapy or targeted therapy the doctor will propose to the patient to participate in the study, give him the information leaflet, collect orally non-opposition, and will complete a survey for evaluation of the general health and potential risk factors for interstitial lung.

Enrollment

34 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women over the age of 18
  • With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010
  • Never received any biotherapy or targeted therapy
  • Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)

Exclusion criteria

  • Refusal to participate in the study
  • Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary
  • Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease)
  • Patient with signs of cardiac decompensation
  • Patient with pulmonary auscultation suggestive of PID
  • Pregnant or lactating woman
  • Psychiatric pathology seriously hindering understanding
  • Difficulty understanding oral French
  • Person deprived of liberty or under legal protection

Trial design

34 participants in 1 patient group

Sample population
Description:
Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
Treatment:
Other: Lung sonography

Trial contacts and locations

1

Loading...

Central trial contact

Muriel PIPERNO, MD; Cyrille CONFAVREUX, MD, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems